Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.4.1.1 (
pyruvate carboxylase
)
1,516
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
An in vivo strategy to apply the activation effect of acetyl-CoA on phosphoenolpyruvate carboxylase (PEPC) and
pyruvate carboxylase
(
PYC
) to increase succinate production in Escherichia coli was studied. This approach relies on the increased intracellular acetyl-CoA and CoA levels by overexpressing E. coli
pantothenate kinase
(
PANK
). The results showed that coexpression of
PANK
and PEPC, and
PANK
and
PYC
, did improve succinate production compared to the individual expression of PEPC and
PYC
, respectively. The intracellular acetyl-CoA and CoA levels were also measured, and each showed a significant increase when the
PANK
was overexpressed. Another effect observed was a decrease in lactate production. The least amount of lactate was produced when
PANK
and PEPC, and
PANK
and
PYC
, were coexpressed. This result showed increased competitiveness of the succinate pathway at the phosphoenolpyruvate and pyruvate nodes for the carbon flux, as a result reducing the carbon flux toward the lactate pathway. The study also demonstrates a feasible method for metabolic engineering to modulate enzyme activity in vivo through specific activators and inhibitors.
...
PMID:Increasing the acetyl-CoA pool in the presence of overexpressed phosphoenolpyruvate carboxylase or pyruvate carboxylase enhances succinate production in Escherichia coli. 1545 51
